David Kamer

Axion BioSystems

Axion BioSystems' suite of live-cell analysis tools offers next-generation solutions for continuous, noninvasive monitoring of in vitro cell models on your benchtop or inside your incubator. From investigating disease mechanisms in neurology and cardiology to developing lifesaving immunotherapies and antivirals, Axion's award-winning products are designed to accelerate scientific breakthroughs and transform therapeutic development from discovery to manufacturing.   Since launching the revolutionary Maestro multielectrode array (MEA) system in 2008, Axion has continuously expanded its offerings, introducing the premier live-cell analyzer Maestro Z in 2019 and the automated live-cell Omni imager in 2023. Featuring real-time, label-free monitoring, powerful software, and scalable throughput, discover how Axion's user-friendly tools can simplify the workflow in any academic, biotechnology, or pharmaceutical lab.   Promoting a culture of collaboration, innovation, inclusivity, and customer commitment, Axion BioSystems has more than 180 employees worldwide and is headquartered in the tech hub of Atlanta, Georgia, USA.